Biolinerx Stock Today
| BLRX Stock | USD 3.16 0.11 3.61% |
PerformanceVery Weak
| Odds Of DistressHigh
|
BioLineRx is trading at 3.16 as of the 16th of March 2025; that is 3.61 percent increase since the beginning of the trading day. The stock's open price was 3.05. BioLineRx has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 16th of December 2024 and ending today, the 16th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 25th of July 2011 | Category Healthcare | Classification Health Care |
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modiin, Israel. Biolinerx operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 3.56 M outstanding shares of which 216.35 K shares are currently shorted by private and institutional investors with about 1.72 trading days to cover. More on BioLineRx
Moving together with BioLineRx Stock
| 0.73 | ENVB | Enveric Biosciences Earnings Call Next Week | PairCorr |
Moving against BioLineRx Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
BioLineRx Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Vice President-Development | Ella Sorani | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, NASDAQ Composite Total, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsBioLineRx can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand BioLineRx's financial leverage. It provides some insight into what part of BioLineRx's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
BioLineRx (BLRX) is traded on NASDAQ Exchange in USA. It is located in Modi?in Technology Park, Hevel Modi'in, Israel, 7177871 and employs 79 people. BioLineRx is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 11.24 M. BioLineRx conducts business under Biotechnology sector and is part of Health Care industry. The entity has 3.56 M outstanding shares of which 216.35 K shares are currently shorted by private and institutional investors with about 1.72 trading days to cover.
BioLineRx currently holds about 43.15 M in cash with (22.61 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.9.
Check BioLineRx Probability Of Bankruptcy
Ownership AllocationThe market capitalization of BioLineRx is $11.24 Million. BioLineRx shows 4.67 percent of its outstanding shares held by insiders and 1.4 percent owned by other corporate entities. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check BioLineRx Ownership Details
BioLineRx Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Envestnet Asset Management Inc | 2024-12-31 | 0.0 | |
| Susquehanna International Group, Llp | 2024-12-31 | 0.0 | |
| Wells Fargo & Co | 2024-12-31 | 0.0 | |
| Cutter & Co Brokerage, Inc. | 2024-12-31 | 0.0 | |
| Atria Wealth Solutions, Inc. | 2024-12-31 | 0.0 | |
| Rathbone Brothers Plc | 2024-12-31 | 0.0 | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 0.0 | |
| Atria Investments Llc | 2024-12-31 | 0.0 | |
| Virtu Financial Llc | 2024-12-31 | 0.0 | |
| Values First Advisors Inc | 2024-12-31 | 166.4 K | |
| Rhumbline Advisers | 2024-12-31 | 43 K |
BioLineRx Historical Income Statement
BioLineRx Stock Against Markets
BioLineRx Corporate Management
| CPA CPA | Chief Officer | Profile | |
| Raziel Fried | Treasurer Director | Profile | |
| Adam Esq | General Compliance | Profile | |
| Jael MSc | QA RA | Profile | |
| CPA MBA | Chief Officer | Profile |
Additional Tools for BioLineRx Stock Analysis
When running BioLineRx's price analysis, check to measure BioLineRx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioLineRx is operating at the current time. Most of BioLineRx's value examination focuses on studying past and present price action to predict the probability of BioLineRx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioLineRx's price. Additionally, you may evaluate how the addition of BioLineRx to your portfolios can decrease your overall portfolio volatility.